Dr Jacqueline C. Barrientos, MD

Hematologist, New Hyde Park
Assistant Professor, Hofstra Northwell School of Medicine
New York

“The Treatment of Relapsed/Refractory CLL with Novel Agents”

Wednesday, April 20, 2016

GLEN Site
Room D 02.1312
8:30 to 9:30 Videoconference: vspo@mcgill.ca

Hôpital Charles-Le Moyne
Salle HN-106
12:00 to 13:00 Videoconference: vspo@mcgill.ca

Hôpital Notre-Dame
Amphithéâtre Deschamps (Room I-1176-2)
17:00 to 18:00 Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

Thursday, April 21, 2016

Hôpital du Sacré-Cœur de Montréal
Room C-5175
8:00 to 9:00

Jewish General Hospital
Room E-711
12:30 to 13:30 Videoconference: vspo@mcgill.ca

Learning Objectives

• Recognize the role of novel CLL agents in the treatment of relapsed/refractory Chronic Lymphocytic Leukemia (CLL)
• Determine how and when to use novel agents in the treatment of CLL
• Explore the clinical experience with novel agents in relapsed/refractory CLL treatment through the review of patients cases

This program has received an educational grant from: Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lilly Oncology, Lundbeck, Merck, Novartis, Pfizer, Roche